Regenerating strength Where it’s lost.

Pioneering biologic therapies to rebuild skeletal muscle — founded on science, driven by need.

Explore Technologies

 

Who Is Myostellar?

Our mission: to give strength to everyone impacted by muscle loss

Myostellar focuses on addressing a major unmet need in skeletal muscle research. Despite the skeletal muscle being one of the largest organs in the body, muscle disorders remain under-treated, with no approved therapies specifically for muscle regeneration. As the demand for effective treatments grows, Myostellar aims to fill this gap by developing innovative solutions for muscle regeneration.

Explore Technologies

Key Areas of Application

Muscular dystrophy

with Duchenne Muscular Dystrophy

Acute muscle loss

and other atrophies

Our Science

bg

Muscle-specific regeneration

Therapeutic targeting of a novel mechanism of action specific to skeletal muscle regeneration.

bg

Activation of satellite cells

Satellite cells are the precursors to skeletal muscle cells and differentiate into myoblasts upon activation.

bg

Minimal fibrosis

 

Facilitates the regeneration of skeletal muscle and recovery of function.

“Myostellar focuses on addressing a major unmet need in skeletal muscle research. As the demand for effective treatments grows, Myostellar aims to fill this gap by developing innovative solutions for muscle regeneration.”

Dr Peter Currie, Co-Founder & CEO

“Through our research, we’re looking to create a future where patient lifespans and quality-of-life are not impacted directly by skeletal muscle loss.”

Dr Mikaël Martino, Co Founder & CSO

Our Team

Meet The Team
Background

Globally-renowned developmental evolutionary and stem cell biologist who studies the genetic basis of skeletal muscle stem cell action during development, evolution, regeneration and disease.
Director of ARMI since 2016, with over 20+ years experience, and 7 patents and multiple licensing deals.

Dr
peter currie

Co-Founder & CEO

Background

Leader in regenerative medicine including immune-centric regenerative strategies and protein engineering.
With 10 patents and Co-Founder of Orio Therapeutics in 2023, looking ahead Professor Martino remains passionate about creating new therapeutics for regenerative medicine.

Dr
mikaël martino

Co-Founder & CSO

Background

Experienced in supporting the development and translation of early-stage medical and pharmaceutical discoveries, from IP identification to post-deal management. Bo has led and supported numerous complex transactions, securing high-value partnerships, licenses and investments with leading industry partners.

Dr
Bo yun

COO & Corporate Development

Our Supporters And Partners

Cureator
grant

Monash University